X0306 4 2019-04-17 1 0001360886 OSIRIS THERAPEUTICS, INC. OSIR 0001008317 FRIEDLI PETER C/O OSIRIS THERAPEUTICS, INC. 7075 ALBERT EINSTEIN DRIVE COLUMBIA MD 21046 1 0 0 0 Common Stock 2019-04-17 4 D 0 10204404 19.00 D 0 D Common Stock 2019-04-17 4 D 0 4103301 19.00 D 0 I By New Venturetec AG Common Stock 2019-04-17 4 D 0 500000 19.00 D 0 I By Daughter Common Stock 2019-04-17 4 D 0 2750 19.00 D 0 I By Spouse On March 12, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Smith & Nephew Consolidated, Inc., a Delaware corporation ("Parent"), Papyrus Acquisition Corp., a Maryland corporation and a direct subsidiary of Parent ("Purchaser") and Smith & Nephew plc, an English public limited company. Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $19.00 per share (the "Offer Price") in cash. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person disclaims beneficial ownership of these securities. /s/ Peter Friedli 2019-04-17